Oliver Lagore Vanvalin Investment Group’s QuantumScape Corp QS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$832 Buy
+200
New +$845 ﹤0.01% 597
2024
Q4
$1.45K Sell
280
-3
-1% -$16 ﹤0.01% 602
2024
Q3
$1.63K Hold
283
﹤0.01% 594
2024
Q2
$1.39K Hold
283
﹤0.01% 630
2024
Q1
$1.78K Hold
283
﹤0.01% 628
2023
Q4
$1.97K Sell
283
-150
-35% -$945 ﹤0.01% 631
2023
Q3
$2.9K Hold
433
﹤0.01% 639
2023
Q2
$3.46K Hold
433
﹤0.01% 613
2023
Q1
$3.54K Sell
433
-40
-8% -$325 ﹤0.01% 530
2022
Q4
$2.68K Hold
473
﹤0.01% 530
2022
Q3
$4K Hold
473
﹤0.01% 466
2022
Q2
$4K Hold
473
﹤0.01% 447
2022
Q1
$10K Buy
+473
New +$8.12K 0.01% 338

Other funds holding QS

Oliver Lagore Vanvalin Investment Group's QS Position: Q2 2025 in Review

Oliver Lagore Vanvalin Investment Group opened a new position in QuantumScape Corp (QS) in Q2 2025: 200 shares worth $832. The stake represents ﹤0.01% of the portfolio and ranks #597 among its holdings. This is a return to the name: Oliver Lagore Vanvalin Investment Group previously reported a position in QS as recently as Q4 2024.

Oliver Lagore Vanvalin Investment Group first reported a position in QS in Q1 2022 and has held it in 13 quarters since. The position peaked at $10K in Q1 2022. 364 funds tracked by Wall St. Rank hold QS as of Q2 2025.

  • Oliver Lagore Vanvalin Investment Group held 200 shares of QuantumScape Corp worth $832 as of Q2 2025.
  • QuantumScape Corp was a new Oliver Lagore Vanvalin Investment Group position in Q2 2025.
  • QuantumScape Corp made up ﹤0.01% of Oliver Lagore Vanvalin Investment Group's portfolio in Q2 2025, its #597 holding.
  • Oliver Lagore Vanvalin Investment Group first reported a position in QuantumScape Corp in Q1 2022 and has held it in 13 quarters since.
  • Oliver Lagore Vanvalin Investment Group's QuantumScape Corp position peaked at $10K in Q1 2022.
  • 364 funds tracked by Wall St. Rank held QuantumScape Corp as of Q2 2025.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2025, filed 10 Jul 2025.